ZEAL - Zealand Pharma A/S ADR - Stock Forecast

Healthcare - Sector
Coverage Stock analysts Price Targets & Ratings Chart Insider Trading

with an average price target of $10.99. This is a potential upside of $10.99 (0%) from yesterday's end of day stock price of $0.

Zealand Pharma A/S ADR's activity chart (see below) currently has 13 price targets and 17 ratings on display.

Stock Analyst Price Targets - Review

Analysts average stock forecasts to be materialized ratio is 66.67% with an average time for these price targets to be met of 98 days.

Most recent stock forecast was given by JOSEPH STRINGER from NEEDHAM on 13-May-2022. First documented stock forecast 05-Sep-2017.

Best performing analysts who are covering ZEAL - Zealand Pharma A/S ADR:

Alan Carr David Lebowitz Joseph Stringer

Analyst name

Rating

Current price target

Potential Upside

Previous price target

Date

Price targets met ratio

Average potential upside

Average Time (Days) For PT To Be Met

Performance score

Buy

$32

$14.41 (81.92%)

$42

3 years 2 months 1 days ago
(13-May-2022)

0/2 (0%)

$21.91 (217.15%)

Buy

4 years 8 months 1 days ago
(13-Nov-2020)

6/6 (100%)

$0.5 (1.45%)

101

Sell

$42

$24.41 (138.77%)

$32

5 years 7 months 29 days ago
(15-Nov-2019)

3/3 (100%)

$10.55 (46.64%)

193

Show more analysts

To gain access for the analyst/ stock price target chart please use a computer

What is ZEAL (Zealand Pharma A/S ADR) average time for price targets to be met?

On average it took 98 days on average for the stock forecasts to be realized with a an average price target met ratio 66.67

Which analyst has the current highest performing score on ZEAL (Zealand Pharma A/S ADR) with a proven track record?

ALAN CARR

Which analyst has the current lower performing score on ZEAL (Zealand Pharma A/S ADR) with a proven track record?

JOSEPH STRINGER

Which analyst has the most public recommendations on ZEAL (Zealand Pharma A/S ADR)?

Alan Carr has 5 price targets and 6 ratings on ZEAL

Which analyst is the currently most bullish on ZEAL (Zealand Pharma A/S ADR)?

Alan Carr with highest potential upside - $24.41

Which analyst is the currently most reserved on ZEAL (Zealand Pharma A/S ADR)?

David Lebowitz with lowest potential downside - -$0

Zealand Pharma A/S ADR in the News

Barclays starts these 2 European pharma stocks at Overweight

Investing.com — Barclays has initiated coverage on Galderma Group AG (SIX:GALD) and Zealand Pharma (NASDAQ:ZEAL) with Overweight ratings, citing distinct growth drivers and long-term value potential in both European pharmaceutical companies. For Galderma, the analysts point to the strong commercial launch of Nemluvio, its recently approved therapy for prurigo nodularis (PN) and atopic dermatitis (AD)....

Zealand Pharma announces closing of collaboration and license agreement with Roche

Company announcement – No. 12 / 2025 Zealand Pharma announces closing of collaboration and license agreement with Roche Copenhagen, Denmark, May 9, 2025 – Zealand Pharma A/S (“the Company” or “Zealand Pharma”) (Nasdaq: ZEAL) (CVR-no. 20045078), a biotechnology company focused on the discovery and development of innovative peptide-based medicines, today announces that all closing conditions...
Show more

To continue looking at which analysts cover the stock please register to the basic or advanced membership

What is AnaChart?